Press Room

    Back

    Press Release - January 12, 2011

    Sernova To Present At The OneMedForum San Francisco 2011 Conference


    Source: Sernova Corp.

    Wednesday, January 12, 2011, 6:00 a.m. EST

    LONDON, ONTARIO - (Marketwire - January 12, 2011) - Sernova Corp. (TSX-V:SVA), a company focused on product development and commercialization of innovative medical technologies for cell therapies, is pleased to announce that its President & Chief Executive Officer, Dr. Philip Toleikis will present an overview of the company's technology and strategic positioning to a select group of biotech industry investors at the OneMedForumSF 2011, Emerging Company Finance Conference on Wednesday, January 12, 2011 at 2:00 p.m. (PT) at the Sir Francis Drake Hotel in San Francisco, California.

    OneMedForum takes place January 11-13, 2011 in San Francisco, CA during the world's largest gathering of healthcare financiers and executives. The Forum will feature presentations by over 100 of the world's most promising emerging life science public and private companies. In 2010, over 1,000 investors participated in the conference. To learn more about the forum, visit www.onemedplace.com.

    Sernova's Cell Pouch System(tm) is a scalable medical device providing a natural "organ-like" environment for therapeutic cells. Once implanted under the skin, it develops into a tissue-engineered pancreas when infused with islets. The natural environment established by the Cell Pouch System(tm) is expected to conserve cell number, and promote natural function thereby increasing cell survival, while significantly increasing the number of treatable patients beyond those with severe disease.

    About Sernova

    Sernova Corp. is a Canadian-based, health- sciences company focused on commercializing medical technologies. Sernova is currently developing a platform technology for a number of serious disease indications, starting with a novel treatment for insulin- dependent diabetes, using the novel Cell Pouch System(TM) and its patented Sertolin(TM) cell technology. According to the American Diabetes Association approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. One out of every 8 dollars spent on health care in the United States is spent on treating diabetes and its complications. Worldwide expenditures on insulin alone are estimated to be $15 billion annually and growing.

    For further information contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 info@sernova.com www.sernova.com

    Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

    This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors - including availability of funds, the results of financing efforts, the results of research and product development activities - that could cause actual results to differ materially from Sernova's expectations are disclosed in Sernova's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

    Back



    Press Releases from:

    2017 2016 2015 2014 2013 2012 2011

    2010 2009 2008 2007 2006 2005 2004

    2003 2002 2001 2000 1999

    Featured News

    2014, January 22

    Sernova’s Disruptive Regenerative Medicine Technologies Set to Improve the Treatment of Chronic Diseases While Reducing Healthcare Costs

    Link

    2012, July 11

    Sernova Corp. developing a tiered approach to the treatment of diabetes

    Publisher: Canadian Investor Magazine
    Author: Rochelle Emnance

    PDF

    2012, July 30

    Feds back local diabetes discovery

    Publisher: London Free Press
    Author: Norman De Bono

    2012, July 30

    Federal program pumps $3 million into new, London business

    Publisher: The London Free Press

    Author: Norman De Bono

    2010 July 10

    Canada's economic action plan supports business innovators

    Publisher: Federal Economic Development Agency for Southern Ontario

    Link

    2007, February 20

    "Transplanted cells may protect against diabetes without forced drug use: An interview with Dr. David White"

    Publisher: StockInterview.com
    Author: Julie Ickes and James Finch

    2006, October 04

    "Sertoli Cells: Mother nature's anti-rejection drug"

    Publisher: StockInterview.com
    Author: James Finch

    2006, August 24

    "Mass marketing diabetes reversal; novel xeno-transplants may offer new hope for type 1 diabetics"

    Publisher: StockInterview.com
    Author: James Finch

    Presentation and Video

    September 11, 2017

    Sernova Fact Sheet

    September 11, 2017

    Sernova's 2017 Corporate Presentation

    PDF Presentation

    Subscribe to Sernova News

Subscribe to our News Dispatch Service

* indicates required




Latest Video and Presentation


Sernova Fact Sheet - / September 11, 2017 Open


Sernova's 2017 Corporate Presentation - PDF Presentation / September 11, 2017 Open

All Presentations →